Last Update 05 Apr 26
Fair value Decreased 29%GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.
Analyst Commentary
Recent Street research has turned more cautious on Gerresheimer, with some analysts revisiting their assumptions on growth, execution, and valuation after the FY25 warning and the reset of estimates into FY26.
Bullish Takeaways
- Bullish analysts see the updated FY26 company guidance as a potential anchor for long term expectations, even if current external estimates are positioned slightly below the low end.
- The cut to short and mid term estimates is viewed by some as a way to reduce earnings risk and create room for upside if operational execution improves from the lowered base.
- Some investors may view the lower consensus price target versus prior levels as creating a more conservative starting point for reassessing risk and reward on the stock.
Bearish Takeaways
- Bearish analysts point to the reduction of the price target to €12.90 from €29 as a sign that previous expectations for growth and profitability may have been too optimistic.
- The fact that FY26 external estimates now sit a touch below the low end of company guidance is seen as a signal of limited confidence in full delivery of management targets.
- Short and mid term estimate cuts following the FY25 warning highlight execution risk, with concerns that further guidance adjustments could weigh on investor sentiment.
- Some analysts argue that until there is clearer evidence of consistent delivery against guidance, the risk profile could constrain any rerating of the shares.
What's in the News
- Management updated earnings guidance for 2025, indicating that revenue movement is expected at the upper end of the forecast range of a 4% to 2% decline or slightly better, with revenues projected around €2.3b to €2.4b (company guidance).
- Gerresheimer expects 2026 revenues of around €2.3b to €2.4b, consistent with the guided range for 2025 (company guidance).
- The management board decided to defer publication of the 2025 annual and consolidated financial statements, which were originally scheduled for 26 February 2026 (company announcement).
Valuation Changes
- Fair Value: the consensus estimate has fallen significantly from €34.17 to €24.40, a reduction of around 29%.
- Discount Rate: essentially unchanged at about 10.19%, indicating a similar assumed risk profile compared with previous models.
- Revenue Growth: the long term revenue growth assumption has edged down from roughly 5.82% to 5.42%.
- Net Profit Margin: the projected net profit margin has eased from about 4.28% to 3.95%.
- Future P/E: the assumed future P/E multiple has been reduced from about 13.63x to 10.65x, pointing to a lower valuation multiple being applied to expected earnings.
Key Takeaways
- The acquisition of Bormioli Pharma and new product lines are expected to significantly boost Gerresheimer's revenue and profitability.
- Strategic facility upgrades and a shift to high-value products aim to enhance margins and improve overall earnings.
- Potential integration risks from Bormioli Pharma acquisition and ongoing financial challenges could affect Gerresheimer's liquidity, margins, and operational stability.
Catalysts
About Gerresheimer- Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
- The acquisition of Bormioli Pharma is expected to propel Gerresheimer's revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company's adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.
- The anticipated organic growth rate of 3% to 5% in 2025, driven by new product lines, a shift towards high-value products, and normalization of operations at facilities affected by prior disruptions, is poised to positively impact Gerresheimer's revenue and profitability.
- The ramping up of new production lines in Skopje and Peachtree City, and the introduction of advanced products such as ready-to-fill syringes and vials, indicates a move towards higher-margin products which is expected to improve net margins and earnings.
- The strategic transitions and capacity expansions at key facilities like the new state-of-the-art hybrid furnace in Lohr, and the restoration of full capacity at Morganton, are likely to enhance production efficiency and contribute positively to future earnings.
- The ongoing trend towards high-value product offerings, such as the shift from standard bulk vials to high-value vials, is positioned to strengthen net margins and improve overall earnings due to superior pricing and market demand for innovative solutions.
Gerresheimer Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Gerresheimer's revenue will grow by 5.4% annually over the next 3 years.
- Analysts assume that profit margins will increase from 1.0% today to 4.0% in 3 years time.
- Analysts expect earnings to reach €104.2 million (and earnings per share of €3.01) by about April 2029, up from €23.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €158.4 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 10.8x on those 2029 earnings, down from 27.5x today. This future PE is lower than the current PE for the GB Life Sciences industry at 27.5x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 10.19%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The integration of Bormioli Pharma presents potential integration risks and associated costs, which could impact overall operational efficiency and margins.
- There is significant seasonal fluctuation in cash flow, with Q1 often showing negative free cash flow figures, which could stress liquidity and financial stability if not managed prudently.
- Ongoing challenges in the moulded glass sector, including decreased demand in the cosmetics market, could negatively impact revenues and operational stability in the short term.
- The company's increased leverage due to the acquisition of Bormioli could, if not carefully managed, lead to financial strain, impacting earnings and investor confidence.
- Delays and disruptions, such as those from natural disasters affecting Morganton, could introduce further operational risks, impacting revenue streams and margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of €24.4 for Gerresheimer based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €46.0, and the most bearish reporting a price target of just €12.5.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €2.6 billion, earnings will come to €104.2 million, and it would be trading on a PE ratio of 10.8x, assuming you use a discount rate of 10.2%.
- Given the current share price of €18.56, the analyst price target of €24.4 is 23.9% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Gerresheimer?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
